California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Feasibility of Endovascular Repair Of Ascending Aortic Pathologies
Recruiting
The purpose of this study is to investigate the outcome of patients with pathologies of the ascending thoracic aorta (diseases in the great blood vessel or artery that leads away from the heart) including type A aortic dissection, retrograde type A aortic dissection, intramural hematoma, penetrating ulcer or pseudoaneurysm who are suitable for endovascular (within the vessel) repair with the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft. Type A aorti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Long Beach Memorial Medical Center, Long Beach, California
Conditions: Aortic Dissection, Intramural Hematoma, Penetrating Ulcer, Pseudoaneurysm
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With HER3-Expressing Solid Tumors
Recruiting
This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of ENV-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The study consists of 2 phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2). The primary objectives of Phase 1 are to characterize the overall safety and tolerability profile of in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Research Site, La Jolla, California
Conditions: Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
Recruiting
This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enrolled participants will be randomized 2:1 to treatment in the experimental arm or the control arm. Participant randomization will be stratified by geographical region (North America vs Europe vs ASIA vs Other), NSCLC histology (squamous vs nonsquamous), and actionable genomic alteration (AGA); (epide... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/01/2025
Locations: OPN Healthcare INC, Glendale, California
Conditions: NSCLC Stage IV
Rigorous Evaluation of Yes and Know, a Fully Virtual Sexual Health and Well-Being Intervention for Youth
Recruiting
This study is a 2-arm cluster randomized controlled trial with approximately 1,200 youth aged 14-19 years to assess the effectiveness of Yes and Know, a sexual health education program. To be eligible, participants must be 14-19 years old and English-speaking. Those in the treatment arm will receive Yes and Know, a synchronous virtual program delivered over multiple sessions totaling nine hours, along with asynchronous online activities and resources. Those in the control arm will receive a simi... Read More
Gender:
ALL
Ages:
Between 14 years and 19 years
Trial Updated:
05/01/2025
Locations: ETR Associates, Watsonville, California
Conditions: Pregnancy Related, Sexually Transmitted Diseases, Adolescent Behavior
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
Recruiting
The goal of this clinical trial is to learn whether IBD patients have better disease outcomes and feel more empowered to manage their condition if they have access to text messaging with their clinical team and if their symptoms are more regularly monitored through text-based surveys. Researchers will compare participants who have access to text-based monitoring, communication and education to participants who have access to text-based education alone. Researchers will also examine if different... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
05/01/2025
Locations: University of California San Diego, San Diego, California
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Colitis
Early Onset Colorectal Cancer Detection
Recruiting
Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagnosed CRC cases and it stands as the first cause of cancer-related death in young men and the second for young women. This study aims to detect EOCRC with a non-invasive test, using a blood-based molecu... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/01/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I, Colorectal Cancer Stage IV, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Neoplasms Malignant
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Recruiting
This is a single center, phase I/Ib clinical trial evaluating the combination of the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of decitabine with cedazuridine (a cytidine deaminase inhibitor that allows for oral administration). The study population consists of adults with advanced/metastatic solid tumor malignancies with germline or somatic mutations in the HRR pathway (i.e., BReas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
Recruiting
This phase II trial tests how well biologically guided radiation therapy (BgRT) and stereotactic body radiation therapy (SBRT) with osimertinib works for the treatment of EGFR positive non-small cell lung carcinoma that has spread from where it first started (primary site) to a limited number of anatomic sites (oligoprogressive). BgRT is radiation that uses specialized imaging to during treatment to target the active tumor and direct radiation to tumors in order to kill and shrink tumor cells. S... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Recruiting
To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University, Palo Alto, California
Conditions: Lymphoblastic Leukemia
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Recruiting
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will receive alectinib alone. Those in Phase 2, Arm B will receive SRS + alectinib. A maximum of 25 cycles (2 years) of alectinib may be administered on study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University, Stanford, California
Conditions: Lung Cancer, NSCLC, Brain Metastases
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Recruiting
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/01/2025
Locations: Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California
Conditions: Breast Cancer, Cognitive Impairments
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Recruiting
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
05/01/2025
Locations: Ascendis Investigational Site, Sacramento, California
Conditions: Growth Hormone Deficiency